WO2026042012 - SINGLE DOMAIN ANTIBODIES AND POLYPEPTIDES CONTAINING SAME
National phase entry is expected:
Publication Number
WO/2026/042012
Publication Date
26.02.2026
International Application No.
PCT/IB2025/058370
International Filing Date
18.08.2025
Title **
[English]
SINGLE DOMAIN ANTIBODIES AND POLYPEPTIDES CONTAINING SAME
[French]
ANTICORPS À DOMAINE UNIQUE ET POLYPEPTIDES LES CONTENANT
Applicants **
INSTITUTE OF MOLECULAR AND CLINICAL OPHTHALMOLOGY BASEL (IOB)
Inventors
HANSEN, Simon Theodor
ROSKA, Botond Miklós
AYUPOV, Temurkhan
Priority Data
63/684,592
19.08.2024
US
63/711,933
25.10.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 4822 | |
| EPO | Filing, Examination, Granting | 44508 | |
| Japan | Filing, Examination, Granting | 3589 | |
| South Korea | Filing, Examination, Granting | 4750 | |
| USA | Filing, Examination, Granting | 15890 |
Total:
73,559
Contact Us
Abstract[English]
Provided herein are sdAbs that have binding specificity for CD71, CD73, CD142, TOMM20 and TOMM70 comprising a CDR1, CDR2, and a CDR3. Also provided herein are fusion proteins, immunoglobulin formats, and conjugates comprising the sdAb.[French]
L'invention concerne des anticorps à domaine unique (sdAb) qui ont une spécificité de liaison pour CD71, CD73, CD142, TOMM20 et TOMM70 comprenant une CDR1, CDR2 et une CDR3. L'invention concerne également des protéines de fusion, des formats d'immunoglobuline et des conjugués comprenant le sdAb.